Jupiros F Tablet is a combination lipid-lowering agent containing Fenofibrate 160 mg and Rosuvastatin 20 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily reduces triglyceride levels and increases high-density lipoprotein cholesterol (HDL-C) by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) by inhibiting cholesterol synthesis in the liver and upregulating LDL receptors, thereby increasing clearance of LDL particles. The combination therapy is beneficial in patients with persistent elevated LDL-C and triglycerides despite monotherapy, offering comprehensive lipid profile improvement. Jupiros F is indicated for adults with primary hypercholesterolemia, mixed dyslipidemia, or patients at high cardiovascular risk requiring aggressive lipid management. It should be used alongside diet and lifestyle modifications. Caution is advised in patients with hepatic or renal impairment, and periodic monitoring of liver function tests, renal parameters, and creatine kinase is recommended to detect potential adverse effects such as myopathy or hepatotoxicity. Jupiros F Tablet should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.